Variable | Overall | HBsAg positive | HBsAg negative | p |
---|---|---|---|---|
No. of patients | 498 | 38 | 460 | - |
Age - Mean [±SD] | 61,00 [±14,05] | 55,42 [±13,62] | 57,32 [±14,95] | 0,45 |
Sex – M/F | M: 54,40% - | M: 57,89% | M: 47,83% | 0,23 |
F: 45,40% | F: 42,11% | F: 52,17% | ||
No. of patients HBsAb + | 90 [18,07%] | 0 | 90 [19,56%] | 0,003 |
No. of patients HBcAb +/ HBsAg - | 134 [26,90%] | 0 | 96 [20,86%] | 0,002 |
No. of patients HBcAb - / HBsAg - | 274 [55,03%] | 0 | 274 [59,56%] | |
Lymphoma type | Indolent: 47,3% - | Indolent: 33,35% - | Indolent: 44,34% - | 0,22 |
Aggressive: 52,7% | Aggressive: 66,65% | Aggressive: 55,66% | 0,22 | |
Rituximab therapy | Yes: 60,30% - | Yes: 18 [47,37%] | Yes 262 [56,95%] | 0,25 |
No: 39,70% | No: 20 [52,63%] | No: 198 [43,04%] | ||
HBV reactivation | 10 [2,01%] | 0 | 10 [2,17%] | 0,22 |
NUC profilaxys/rescue therapy | 38/10 | 38/0 | 0/10 | <0,0001 |
“Per year Incidence of reactivation” [mean ± SD] | 1,71% | 0 | 2,04% | <0,0001 |
±2,43% | ±2,97 | |||
Liver related decompensations/hospitalizations/deaths | 0% | 0% | 0% | - |